Bacainn Therapeutics’ Ashley Mansell to Present on BT032, a Novel First-in-Class NLRP1 and NLRP3 Inhibitor, at the 3rd Inflammasome Therapeutics Digital Summit

CONCORD, Mass.–(BUSINESS WIRE)–Bacainn Therapeutics, Inc., a biotechnology company focused on developing novel therapies that target the innate immune system to address uncontrolled inflammation, today announced that Ashley Mansell, PhD, Senior Director of Research & Development, Bacainn Therapeutics & Principal Investigator, Hudson Institute of Medical Research, will present at the 3rd Inflammasome Therapeutics Summit being held virtually on November 16 – 18. Dr. Mansell’s presentation will focus on the discovery and characterization of BT032, a novel dual NLRP1 and NLRP3 inhibitor, and its potential application for the treatment of pulmonary inflammation.

Details of Presentation:

MEETING: Inflammasome Therapeutics Summit

SESSION: Stream B – Advances in Pre-Clinical Models & Proof-of-Concept Trials

TITLE: BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation

TIMING: Wednesday, November 17, 2021, 11:30 am ET – Digital Event

About Bacainn Therapeutics

Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation. The company was founded on novel and extensive insights into neutrophil and inflammasome biology which allow for potentially new and bold approaches to treating inflammatory diseases. Bacainn’s lead asset, BT051, is currently in clinical development for the treatment of moderate to severe ulcerative colitis. Identification of proprietary compounds that simultaneously block NLRP1 and NLRP3 inflammasomes led to the breakthrough discovery of BT032, which is being investigated for therapeutic application in respiratory and other inflammasome-mediated diseases. Founded in 2017, Bacainn is funded by Morningside Ventures. For more information,


Wendy Gabel
Kendall Investor Relations
[email protected]